VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
复制标题
DOI：
10.1038/nm.4308
复制
发表时间：
2017-05
期刊：
影响因子：
82.9
通讯作者：
Sharma P
中科院分区：
文献类型：
--
作者：
Gao J;Ward JF;Pettaway CA;Shi LZ;Subudhi SK;Vence LM;Zhao H;Chen J;Chen H;Efstathiou E;Troncoso P;Allison JP;Logothetis CJ;Wistuba II;Sepulveda MA;Sun J;Wargo J;Blando J;Sharma P
迄今为止，抗CTLA-4（ipilimumab）或抗PD-1（nivolumab）单药治疗尚未在前列腺癌患者中显示出显著的临床获益。为了确定前列腺肿瘤微环境中的其他免疫抑制途径，我们在术前临床试验中评估了来自患者的未经治疗和伊匹单抗治疗的肿瘤。PD-L1和VISTA抑制分子在独立的巨噬细胞亚群上增加。我们的数据表明，VISTA是ipilimumab治疗后前列腺肿瘤中的另一种代偿性抑制途径。
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not demonstrated significant clinical benefit in patients with prostate cancer. To identify additional immune inhibitory pathways in the prostate tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients on a pre-surgical clinical trial. PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages. Our data suggest that VISTA is another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.